Early diagnosis of HBV-related liver cancer by EVs antibody capture technology

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023718

Enrollment

Unknown

Registered

2019-06-08

Start date

2020-01-01

Completion date

Unknown

Last updated

2019-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver disease

Interventions

Gold Standard:HBsAg is positive for more than 6 months and there is 1 of the following 3 phases: 1. Two or more (ultrasound, CT, MRI) techniques confirmed as early HCC

2. Pathological liver puncture diagnosis of early patients with HCC

3. Other technical means diagnosed as patients with early HCC.

Index test:exosome antibody

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: HBsAg is positive for more than 6 months and there is 1 of the following 3 phases: 1. Two or more (ultrasound, CT, MRI) techniques confirmed as early HCC; 2. Pathological liver puncture diagnosis of early patients with HCC; 3 Other technical means diagnosed as patients with early HCC.

Exclusion criteria

Exclusion criteria: 1. Advanced HCC, or HBsAg-negative early HCC; 2. Patients who do not sign informed consent or refuse to participate in the study.

Design outcomes

Primary

Measure	Time frame
exosome antibody;SPE, SEN, ACC, AUC of ROC;	—

Countries

China

Contacts

Public ContactHongshan Wei

Beijing Ditan Hospital, Capital Medical University

drwei@ccmu.edu.cn+86 13810033129

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026